# TB-500 Research: Mechanism, Cardiac, Wound, and Neurological Findings > TB-500 research, read as a codex: G-actin sequestration, the PINCH-ILK-Akt cardiac result, wound re-epithelialization, the non-monotonic stroke dose-response, and the human-data limit. The mechanism, the established full-length findings, and the caveats — each inscribed and sealed to its study. ## TB-500 Mechanism of Action: G-Actin Sequestration TB-500 research begins with actin. The fragment carries the LKKTETQ motif by which thymosin beta-4 binds monomeric (globular) actin in a 1:1 complex, capping both ends of the monomer so it cannot polymerize [1]. X-ray crystallography of a gelsolin-domain-1-thymosin beta-4 hybrid bound to actin, resolved at 2 angstroms, established this as the structural basis of actin buffering for the WH2 family of proteins [1]. By holding a reserve of unpolymerized actin, the protein governs cytoskeletal dynamics, cell migration, and motility. That single binding event radiates outward. In injury models the parent protein is associated with accelerated migration of keratinocytes, endothelial cells, and progenitor cells; with angiogenesis; with anti-inflammatory and anti-apoptotic signaling; and with reduced myofibroblast number and scar formation [5]. The honest qualifier is structural, not rhetorical: these pathways were mapped largely with full-length thymosin beta-4. Whether the isolated Ac-LKKTETQ heptapeptide reproduces them at peptide-research doses is not established in controlled human trials. ## The cardiac finding: PINCH-ILK-Akt survival signaling In mice, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt; after coronary artery ligation it upregulated ILK/Akt, enhanced early myocyte survival, and improved cardiac function, in a result published in Nature [2]. More recent work delivered thymosin beta-4 locally from a functionalized self-assembling peptide scaffold to activate cardiac repair processes, showing the direction engineering has taken the cardiac question [15]. The record is not uniformly positive, and a research codex sets the null results beside the positive ones. Systemic thymosin beta-4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study, and a chronic study in dystrophin-deficient (mdx) mice increased regenerating fibers but did not improve muscle strength, cardiac function, or fibrosis [10]. Animal cardiac benefit, where it appears, is a finding for the parent protein; human cardiac efficacy of the fragment is unproven. ## Does TB-500 help wound healing? In a rat full-thickness wound model, thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, raised wound contraction by at least 11% by day seven, and increased collagen deposition and angiogenesis; as little as 10 picograms stimulated keratinocyte migration two- to three-fold [3]. Clinical-grade topical thymosin beta-4 (RGN-259, a 0.1% ophthalmic solution) promoted corneal healing and improved corneal integrity in the eye program [8]. These re-epithelialization figures are full-length thymosin beta-4 results; fragment efficacy in humans is unproven. ## Does TB-500 have neuroprotective effects on the brain? In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 — 2, 12, or 18 mg/kg starting 24 hours post-stroke, then every three days for four further doses — improved neurological function at 2 and 12 mg/kg, significantly from day 14 through day 56, but gave no significant benefit at 18 mg/kg, with a modeled optimal dose near 3.75 mg/kg [4]. The shape of that response is the lesson: it is non-monotonic, so more is not better, which directly undermines community "loading" rationales. These are animal data; an injectable thymosin beta-4 acute-stroke human trial was withdrawn. ## Does TB-500 affect the heart? In mice, thymosin beta-4 activated the PINCH-ILK-Akt survival pathway and improved cardiac function after coronary ligation [2], and engineered local-delivery work continues to pursue cardiac repair [15]. Some models, however, showed no benefit — systemic thymosin beta-4 did not attenuate myocardial ischemia-reperfusion injury in a porcine study [10]. Human cardiac efficacy of the TB-500 fragment is unproven. ## Does TB-500 promote angiogenesis and is that a safety concern? Thymosin beta-4 is pro-angiogenic, driving endothelial migration and new vessel formation, which is part of why it aids repair [5]. The same property is a theoretical oncologic concern: thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis, so the pro-migratory, pro-angiogenic machinery that supports healing could in principle support tumor progression [10]. Human safety data for the fragment are limited, which is why this codex marks the signal with a crimson caveat rather than dismissing it. ## TB-500 and BPC-157 in the Recovery Literature TB-500 and BPC-157 are distinct peptides that recur together in the recovery conversation. A 2026 Sports Medicine narrative review lists both among unapproved peptides that show favorable tissue-repair outcomes in animal models but for which rigorous human safety data are scarce, with potential for serious harm, operating largely outside regulatory oversight [10]. This codex summarizes the published research on TB-500 and thymosin beta-4; it does not compare products, rank vendors, or endorse either compound. ## Are there any human clinical trials on TB-500? No completed controlled trials of the TB-500 heptapeptide exist for any indication. Human data exist only for full-length thymosin beta-4: a randomized, placebo-controlled Phase 1 intravenous study in 40 healthy volunteers, well tolerated to 1260 mg with dose-proportional pharmacokinetics [6], and topical ophthalmic thymosin beta-4 (RGN-259) in corneal and dry-eye work [8]. An early injectable acute-stroke trial was withdrawn. The [human clinical status](/research) of the fragment remains untested. --- A gothic research codex of the thymosin beta-4 record — inscribed from the literature, sealed to its sources, and dispensing nothing.